Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Merrimack Pharmaceuticals (NASDAQ:MACK) and Intuitive Surgical (NASDAQ:ISRG).
Merrimack Pharmaceuticals (MACK)
Robert W. Baird analyst Michael Ulz maintained a Hold rating on Merrimack Pharmaceuticals yesterday and set a price target of $4. The company’s shares closed yesterday at $4.26, close to its 52-week low of $3.34.
According to TipRanks.com, Ulz is ranked 0 out of 5 stars with an average return of -6.5% and a 43.1% success rate. Ulz covers the Healthcare sector, focusing on stocks such as Mersana Therapeutics Inc, Alexion Pharmaceuticals, and Karyopharm Therapeutics.
Currently, the analyst consensus on Merrimack Pharmaceuticals is a Hold with an average price target of $4, a -6.1% downside from current levels. In a report issued on October 19, Cowen & Co. also maintained a Hold rating on the stock.
.
See today’s analyst top recommended stocks >>
Intuitive Surgical (ISRG)
Raymond James analyst Michael Gibbs maintained a Buy rating on Intuitive Surgical on October 19 and set a price target of $630. The company’s shares closed yesterday at $511.41.
According to TipRanks.com, Gibbs is ranked #786 out of 4892 analysts.
Intuitive Surgical has an analyst consensus of Strong Buy, with a price target consensus of $610.44, a 19.4% upside from current levels. In a report issued on October 9, Piper Jaffray also upgraded the stock to Buy with a $600 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
